Clinical trials: Antibody
Guillain-Barré Syndrome, Miller Fisher Syndrome
International Guillain-Barré Syndrome Outcome Study
International GBS Outcome Study (IGOS) is a study conducted by the members of the Inflammatory Neuropathy Consortium (INC) and Peripheral Nerve Society (PNS) on disease course and outcome in Guillain-Barré syndrome (GBS).
- Trial name
- IGOS (NCT01582763)
- Where
- 138 sites in United States, Argentina and 19 more
- Volunteers
- 2,000 people
- Sponsor
- Erasmus Medical Center
Advanced Kidney Cancer
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced kidney cancer.
- Trial name
- NCT03540199
- Testing
- Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer, cryotherapy
- Where
- China
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Idiopathic Thrombocytopenic Purpura
Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients
It is a phase III extension study to assess safety and immunogenicity of long-term therapy with GNR-069 in patients with idiopathic thrombocytopenic purpura
- Trial name
- NCT05492409
- Testing
- GNR-069
- Where
- 13 sites in Russia
- Volunteers
- 160 people
- Sponsor
- AO GENERIUM
Small Cell Lung Cancer
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung…
- Trial name
- SKYSCRAPER-02 (NCT04256421)
- Testing
- Tiragolumab, Atezolizumab, Carboplatin
- Where
- 121 sites in United States, Australia and 21 more
- Volunteers
- 490 people
- Sponsor
- Hoffmann-La Roche
Hodgkin Disease, Peripheral T Cell Lymphoma
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT01716806
- Testing
- brentuximab vedotin, bendamustine, dacarbazine
- Where
- 54 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Seagen Inc.
Head and Neck Cancer
Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer
The purpose of the study is to investigate efficacy and safety boron neutron capture therapy (BNCT) administered in combination with cetuximab in the treatment of head and neck cancer that has recurred locally following…
- Trial name
- NCT00927147
- Testing
- BNCT, cetuximab
- Where
- Finland
- Volunteers
- 17 people
- Sponsor
- Boneca Corporation
Soft Tissue Sarcoma, Sarcoma,Soft Tissue
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
This study is being done to find out whether the study drug Retifanlimab, a monoclonal antibody against the PD-1 protein, combined with gemcitabine and docetaxel, is a safe and effective treatment for your disease.
- Conditions
- Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
- Trial name
- NCT04577014
- Testing
- Retifanlimab, Gemcitabine, Docetaxel
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ulcerative Colitis, Ulcerative Colitis Chronic
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT06598943
- Testing
- Eltrekibart, Mirikizumab
- Where
- 207 sites in United States, Argentina and 19 more
- Volunteers
- 143 people
- Sponsor
- Eli Lilly and Company
Advanced or Metastatic Biliary Tract Cancer
A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 as single agent in HER2-positive unresectable locally advanced or metastatic biliary tract cancer patients who have…
- Trial name
- NCT04837508
- Testing
- MRG002
- Where
- 7 sites in China
- Volunteers
- 86 people
- Sponsor
- Shanghai Miracogen Inc.
Primary Immunodeficiency Disease
IVIG Boya: Safety, Efficacy, and Pharmacokinetics
The goal of this phase 3, open-label, single-group clinical trial is to assess the efficacy of Boya IVIG in maintaining the mean number of serious bacterial infections to less than one per year in participants with primary…
- Trial name
- BoyaIVIG (NCT06150833)
- Testing
- Boya IVIG
- Volunteers
- 50 people
- Sponsor
- Azidus Brasil
Hemophagocytic Lymphohistiocytosis (HLH), Secondary Hemophagocytic Lymphohistiocytosis
Efficacy of Short Course of Intravenous Dexamethasone and Intravenous Immunoglobulin Therapy in Infection-Related Secondary Hemophagocytic Lymphohistiocytosis (isHLH)
Rationale/Gaps in Existing Knowledge: Therapy of Infection-associated Secondary Hemophagocytic lymphohistiocytosis (sHLH) in adult lacks evidence from randomized trial guiding first-line immunomodulation and current therapeutic…
- Trial name
- isHLH-IVD/IVIg (NCT07861776)
- Testing
- Intravenous Immunoglobulin (IVIg) therapy, Intravenous Dexamethasone (IVD) therapy, Targeted antimicrobial therapy & standard care
- Volunteers
- 116 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared…
- Trial name
- IMpower150 (NCT02366143)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Carboplatin
- Where
- 240 sites in United States, Argentina and 24 more
- Volunteers
- 1,202 people
- Sponsor
- Hoffmann-La Roche
Pemphigus, Dermatologic Disease
Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
Pemphigus diseases are life-threatening chronic autoimmune blistering diseases characterized by split formation within the epidermis and surface-close epithelia accompanied by acantholysis.
- Trial name
- RITUX4 (NCT05898308)
- Testing
- RiTUXimab Injection
- Where
- 34 sites in France, Guadeloupe
- Volunteers
- 133 people
- Sponsor
- University Hospital, Rouen
Celiac Disease, Ultrasound
Small Bowel Ultrasound and Antibody Levels in Celiac Disease Activity
This observational study aims to evaluate the relationship between small bowel ultrasound findings and tissue transglutaminase (tTG) antibody blood levels in assessing celiac disease activity.
- Conditions
- Celiac Disease, Ultrasound, Tissue Transglutaminase Antibody, Small Bowel Ultrasonography
- Trial name
- NCT07453589
- Testing
- Small bowel ultrasonography, Serological testing
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Assiut University
Autoimmune Diseases, Mental Disorders Diagnosed in Childhood
Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)
Recent research studies of early onset-obsessive compulsive disorder (OCD) and Tourette's syndrome have questioned whether autoimmunity could play a role in the development of these conditions.
- Conditions
- Autoimmune Diseases, Mental Disorders Diagnosed in Childhood, Schizophrenia
- Trial name
- NCT00001768
- Testing
- Intravenous immunoglobulin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Mental Health (NIMH)
Hypereosinophilic Syndrome
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.
- Trial name
- DESTINY (NCT05334368)
- Testing
- Depemokimab
- Where
- 60 sites in United States, Argentina and 14 more
- Volunteers
- 110 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis
This study was intended to evaluate the safety and efficacy of intravenous (IV) ACZ885 and oral methotrexate (MTX) therapy in patients with early rheumatoid arthritis (RA)
- Trial name
- NCT00487825
- Testing
- Canakinumab (investigational), Methotrexate (MTX)
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 78 people
- Sponsor
- Novartis
Leukemia
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
RATIONALE: Giving combination chemotherapy before a stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the transplanted stem cells.
- Trial name
- NCT00049517
- Testing
- sargramostim, busulfan, cyclophosphamide
- Where
- 99 sites in United States, Israel
- Volunteers
- 657 people
- Sponsor
- Eastern Cooperative Oncology Group
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)
- Trial name
- DAYLIGHT (NCT04964089)
- Testing
- KSI-301, Aflibercept
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Kodiak Sciences Inc
Acute Lymphoblastic Leukemia
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
The purpose of this study is to determine the dose of the bispecific T cell engager blinatumomab (MT103) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and to assess whether this…
- Trial name
- NCT01471782
- Testing
- Blinatumomab
- Where
- 30 sites in United States, Austria and 5 more
- Volunteers
- 93 people
- Sponsor
- Amgen Research (Munich) GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.